Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.41105 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Lin Cai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
JS005 is a novel anti-IL-17A monoclonal antibody. A Phase Ia study (Study 1) in healthy adults, followed by a Phase Ib/II study (Study 2) in patients with moderate to severe plaque psoriasis (PsO), were designed to evaluate the safety, efficacy, and pharmacokinetic characteristics of JS005. Study 1 was a double-blind, randomized, placebo-controlled, single dose-escalation (15, 60, 150, 300, and 600 mg) study. Forty healthy participants were enrolled. Study 2 consisted of a dose-escalation (60, 150, 300, or 600 mg) phase Ib, and a multicentre, double-blind, placebo-controlled phase II administering JS005 150, 300 mg, or placebo once weekly from week 0 to 4 and once every 4 weeks from week 5 to 12. Forty and 143 patients were enrolled in phases Ib and II, respectively. The exposure of JS005 increased linearly with dosage, while the treatment-emergent adverse events did not show this trend. JS005 was well tolerated in both populations. In phase II of Study 2, the proportion of patients with at least a 75% improvement in the Psoriasis Area and Severity Index at week 12 was significantly higher in each JS005 group than in the placebo group (p < 0.001 for all comparisons). JS005 was highly effective in PsO patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Beijing, China.
- Phase I Clinical Trial Ward, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Zhejiang Provincial People's Hospital, Hangzhou, China.
- Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
- Peking University Third Hospital, Beijing, China.
- Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Zitieren
APA
Cai, L., Liu, H., Mu, Z., Tao, X., Zhang, L., Zhang, C., Li, Y., Zhang, G., Zhang, F., Dong, X., Li, C., Chen, A., Wu, Z., Zhu, Y., Zhang, M., Liu, J., Li, A., & Zhang, J. (2025). Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.41105
Vancouver
Cai L, Liu H, Mu Z, Tao X, Zhang L, Zhang C, et al. Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.41105
BibTeX
@article{Cai2025,
author = {Cai, Lin and Liu, Huichen and Mu, Zhanglei and Tao, Xiaohua and Zhang, Litao and Zhang, Chunlei and Li, Yumei and Zhang, Guoqiang and Zhang, Furen and Dong, Xiuqin and Li, Chengxin and Chen, Aijun and Wu, Zhuning and Zhu, Yuxian and Zhang, Mengqi and Liu, Jiangnian and Li, Aiming and Zhang, Jianzhong},
title = {Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.41105}
}
EUVIMED